Panelists discuss how the interpretation of HER2 IHC scores informs treatment decisions in NSCLC, including adherence to ASCO/CAP guidelines and strategies for managing equivocal results.
Joseph M. Scandura, MD, PhD, discusses the phase 2 SENTRY-2 study evaluating single-agent selinexor in JAK inhibitor–naive myelofibrosis.
Samer A. Al’Hadidi, MD, discusses factors influencing early use of chimeric antigen receptor T-cell therapy in patients with relapsed/refractory multiple myeloma.
Brandon G. Smaglo, MD, FACP, discusses ongoing research with novel RAS inhibitors in pancreatic cancer.
Key Points. The cumulative incidence of SCNSL was 2.6% at two years with death and relapse without CNS involvement as competing risksThe most significant p
An abstract is unavailable.
Key Points. Chemo conditioning with busulfan- or treosulfan-based regimens yields comparable outcomes for allo-HSCT in children with ALL.Either regimen can
One year after the Centers for Medicare & Medicaid Services made the decision to pay for patient navigation services, data from early adopters show that…
In an interview, Antoni Vilaseca Cabo, MD, discussed the clinical activity of TAR-210 in patients with non-muscle invasive bladder cancer.
